FDA approves J&J's bladder cancer 'pretzel' approach Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 10 September, 2025

Endpoints News returns to Boston’s State Room to announce the 2025 class of biotechs worth watching. Join the live unveiling and see the industry’s next chapter come into focus. Which biotechs will make the leap? Join us.

presented by The new blue­print for biotech: RNA edit­ing and ra­di­oli­gand ther­a­py

spotlight Will the XBI ever go up again? Join Post-Hoc Live Wednesday at 11 a.m. ET

news Novo Nordisk to cut 9,000 jobs, posts another profit warning as it refocuses on core meds FDA to ramp up drug ad enforcement, end key loophole under White House order J&J’s ‘pretzel’ drug-device therapy wins US approval for certain bladder cancers

Sep 23 11:00am ET Data you can trust: Setting the bar for ML/LLM-extracted real-world data sponsored by Flatiron Sep 25 11:00am ET Leveraging acoustic focusing for fast and precise high-parameter flow cytometry panels sponsored by Thermo Fisher Oct 02 10:30am ET Unlocking patient access: Modernizing clinical trial regulatory frameworks and trial delivery sponsored by Lilly Oct 21 11:00am ET AI in life sciences: Reimagining teams, technology and partnerships for the future sponsored by Zaidyn by ZS

ESMO 2025's most critical readouts are coming — join our post-conference recap to decode what the data means for your pipeline. Register now.

endpoints pharma Lundbeck to transfer commercial drugs to three partners in 27 markets A former NIH director reflects on genomic medicine and political 'decapitation' HHS outlines vaccine, drug strategy in new MAHA report Regeneron patent deal with Sandoz clears path for new Eylea biosimilar launch in 2026 Samsung Bio secures $1.3B contract with ‘large-sized’ US pharma customer

in case you missed it 1. Ideaya touts trio of cancer drugs as it eyes spot in precision oncology market 2. In first-of-its-kind setup, Lilly offers startups free access to its AI models in exchange for data 3. Novartis to spend $1.4B on Tourmaline Bio, gaining new heart drug 4. Trump may exempt some pharma products from tariffs in future trade deals 5. Bertozzi-advised Ridge Bio lands $25M to help drugmakers come up with better ADCs